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Abstract
Kriemler, Susi, Flavia Bu¨rgi, Christian Wick, Birgit Wick, Melanie Keller, Urs Wiget, Christian Schindler, Beat
A. Kaufmann, Malcolm Kohler, Konrad Bloch, and Hans-Peter Brunner-La Rocca. Prevalence of acute
mountain sickness at 3500 m within and between families: A prospective cohort study. High Alt Biol Med
15:000—000, 2014.—Aim: To investigate symptoms, prevalence and associated factors of acute mountain
sickness (AMS) in families upon a fast ascent to 3450 m.
Methods: 87 children, 70 adolescents, and 155 parents (n = 312) were assessed for AMS 8–10 and 20–24 hours
after fast passive ascent by the Lake Louise Score (LLS). Pain sensitivity and oxygen saturation (SO2) were
measured and familial clustering was assessed.
Results: AMS prevalence was significantly lower in children (21%) compared to adolescents (34%) and adults
(39%) on day 1 ( p< 0.05), but not on day 2 (18% vs. 19% and 25%). Cumulative prevalence of AMS was 30,
37, and 45% in children, adolescents, and adults, respectively ( p< 0.001). Familial clustering of AMS was
consistent and explained 25%–50% of variability in AMS. Pain sensitivity significantly increased from low to
high altitude and was higher at low altitude in those with compared to those without AMS. SO2 at high altitude
was not related to the presence of AMS.
Conclusions: After fast ascent to 3500 m, AMS prevalence was lower in children than in adolescents and adults
on day 1, but not on day 2. Thus, children may travel at least as safely to an altitude of 3500 m as adolescents
and adults, even if risk factors (pain sensitivity and heredity) are present.
Key Words: children; families; high altitude; oxygen saturation; pain sensitivity
Introduction
Worldwide, several hundred thousands of chil-dren travel for recreational or professional reasons of
the families to high altitude (HA) where acute mountain
sickness (AMS) can affect people of all ages (Hackett and
Roach, 2001; Imray et al., 2010). AMS is a symptom com-
plex comparable to an ‘‘alcohol hangover’’ consisting of
headache, appetite loss, nausea, vomiting, dizziness, fatigue,
and sleep disturbance that occurs above altitudes of 2500,m.
Its prevalence increases with altitude and speed of ascent,
ranging from 9%–25% at 2500–3000 m to 40%–60% at
4500 m in adults (Bartsch and Saltin, 2008). AMS prevalence
rates varied upon exposure among different groups (i.e., older
versus younger adults, children versus adults, or females
versus males), but differences were not consistent and may be
related to the use of different AMS definitions and ques-
tionnaires, different modes (active versus passive)/rates of
ascent, prior acclimatization, and possibly also by genetic
susceptibility (Schneider et al. 2002; Kriemler et al. 2006;
Moraga et al. 2008; Bloch et al. 2009; Richalet et al. 2012).
There are only scarce data with small sample sizes about
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AMS prevalence in prepubertal and pubertal children
( = adolescents) (Yaron et al., 2002; Bloch et al., 2009) and
hardly any data in comparison to adults (Moraga et al. 2008).
The precise pathogenesis of AMS is not yet clear. The
existence of cerebral dysfunction possibly due to mild cere-
bral oedema as a consequence of inadequate acclimatisation
to hypobaric hypoxia is the dominant hypothesis (Hackett
and Roach, 2001; Imray et al., 2010). Yet, oxygen saturation
(SO2) has been shown to be (Roach et al., 1998; Karinen
et al., 2010) or not to be (Chen et al., 2012; Wagner et al.,
2012) related to AMS. Furthermore, the individual’s sensi-
tivity to pain might play a role in determining the severity and
prevalence of AMS symptoms (by sympathetic activation) as
hypoxia is known to reduce the pain, taste, or tactile threshold
to sensory stimuli as shown in nonacclimatized lowlanders
upon acute exposure to HA (Noel-Jorand et al., 1996).
Whether children perceive pain differently compared to
adults under normoxic or hypoxic conditions that might po-
tentially influence the occurrence or severity of AMS
symptoms has never been studied. We, therefore, tested the
prevalence and distribution of symptoms of AMS in children
and adolescents of both genders in comparison to their par-
ents upon fast ascent to an altitude of 3450—3650 m over the
first 2 days of exposure. We further tested the relation be-
tween the individual perception of pain, SO2, and AMS.
Methods
Design
The study was performed in the summers of 2005, 2007,
and 2009. Participants were investigated before and after
ascent to HA. Baseline tests were performed at LA (450 m,
barometric pressure 718 mmHg) within 4 weeks prior to as-
cent or 2 months after ascent. The families reached altitude
by train in approximately 3 hours. The tests were repeated 8–
10 h after arrival on day 1 (HA1), and 20–24 h after arrival in
the morning of day 2 (HA2) after an overnight stay at the
research station at 3450 m (2005 and 2007) or a nearby lo-
cated mountain hut at 3650 m (2009), which was reached
after a 45 min walk (Fig. 1). The experimental protocol was
approved by the ethics committees of the ETH Zu¨rich and the
University of Basel. All participants or their legal represen-
tatives provided oral and written informed consent.
Study participants
A total of 87 prepubertal children (34 girls; Tanner stage
1), 70 adolescents (33 girls; Tanner stage > 1), and at least
one biological parent (88 fathers and 67 mothers) were re-
cruited through announcements in the Swiss Alpine Club
journal (total N = 312). Exclusion criteria were symptoms and
signs of cardiovascular or pulmonary abnormalities, any
sleeping problems, previous history of perinatal pathology,
and those with a recent (within 2 months) history of respi-
ratory infections. Subjects were not allowed to stay at alti-
tudes above 2000 m during 2 months prior to the study. The
day prior and during all testing, subjects were not allowed to
take any drugs other than acetaminophen. They abstained
from substances such as alcohol or caffeine and they had a
minimum of 8 h of night rest prior and during the study.
Measurements
Physical examination. An physical exam, including Tan-
ner stage (for youth) and the cardiopulmonary system, was ta-
ken at LA and daily at HA. The clinical exam of AMS was done
right before or after the completion of the questionnaires. It
included the documentation of the mental state, of ataxia by the
‘‘heel-to-toe walking,’’ and of peripheral edema.
FIG. 1. High altitude research station of Jungfraujoch (3450 m) and hut of Mo¨nchsjoch (3650 m), Switzerland.
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AMS questionnaires. AMS was assessed by the adult
version of the Lake Louise AMS Scoring system (LLS)
(Roach et al., 1993) and a single question of the AMS-C
score of the environmental symptoms questionnaire (ESQ)
(Sampson et al., 1983). The latter question asked: ‘‘Do you
feel sick’’? on a 6-point Likert scale. The LLS is composed of
five items that are graded from 0 (not present) to 3 (severe),
including headache, gastrointestinal symptoms (nausea, vo-
miting, loss of appetite), dizziness, fatigue, sleep disturbance,
and three clinical items including mental state, ataxia, and
peripheral edema with a total score ranging from 0 to 23.
Sleep disturbance between HA1 and HA2 was taken for the
score of HA1 and HA2, as it makes no sense to include sleep
disturbances from low altitude. Only in children, the child
version of the LLS (CLLS), a modified questionnaire for
children based on the LLS for adults and a published child
version of the LLS, was used in addition (see Appendix 1)
(Southard et al., 2007). An LLS-Score of ‡ 5 was defined as
diagnostic for AMS (Roach et al. 1993). Children, adoles-
cents, and adults answered the questionnaire independently
of each other. An investigator was always present and an-
swered all questions by the subjects in a neutral way. The
intake of painkillers to treat headaches was whenever pos-
sible postponed until the questionnaires were filled out.
The cold pressure task (CPT) is a method to assess pain
tolerance in humans (von Baeyer et al., 2005). It includes the
assessment of the time until the person has to withdraw the
hand after putting the non-dominant hand in water of 5C
because of pain or discomfort (maximum duration 240 sec)
(von Baeyer et al., 2005). The CPT is widely used, also in
children (von Baeyer et al., 2005), and is free of interference
factors such as nausea, fatigue, fear of pain-inducing thera-
pies, and does not cause negative effects (von Baeyer et al.,
2005). Initially, the hands were washed with warm soap
water. Thereafter, the non-dominant hand was put in water of
36C for 5 min to standardize initial temperature of the ex-
tremity. The hand was then taken out of the water, dried with
a towel, and put into ice water of 5C up to a marked position
5 cm proximally of the wrist. The water was softly stirred by
an investigator to prevent the water surrounding the hand
from warming up.
The arterial oxygen saturation (SO2) was measured twice
noninvasively by pulse oximetry (OxiMax N-595, Nellcor,
Leuag AG, Stans, Switzerland) from the index finger; once
when going to bed after a 10 min rest period and again before
getting out of bed in the next morning. Values were noted at
the end of each minute of assessment and the average of the
last 5 min was taken for analyses.
Statistics
Numerical data are described by mean and SD when nor-
mally distributed or by median and interquartile range oth-
erwise. Differences among AMS scores between the three
study arms and by gender were initially assessed using re-
gression analyses. We used mixed linear models with total
AMS scores at HA1 and HA2, respectively, as dependent
variables, generation, and gender as fixed factors, and the
family (cluster) as random effect. We also tested whether the
intake of painkillers did change results. Corresponding ana-
lyses for binary endpoints including analyses of concordance
of AMS prevalence within families in families with both
parents taking part in the study were performed using mixed
logistic regression models. In secondary analyses, potential
Table 1. Characteristics of the Population
Females Males
Children Adolescents Adults Children Adolescents Adults
Number n 34 33 67 53 37 88
Age years 9.0 – 1.3 12.8 – 1.7 42.8 – 5.4 10.1 – 1.7 13.4 – 1.9 44.9 – 8.2
Weight kg 27.9 – 4.6 44.0 – 10.6 60.7 – 8.1 32.0 – 6.6 47.3 – 10.9 76.2 – 8.7
Height cm 133.8– 8.6 154.8 – 10.6 166.2– 4.4 140.1 – 10.8 160.9– 10.9 177.7 – 6.5
previously exposed to > 3000m
(sleeping altitude)
n (%) 12 (36%)* 16 (48%)* 60 (91%) 24 (45%)* 21 (58%)* 76 (87%)
days over 3000 m days 0 (0 to 1)*** 0 (0 to 1)*** 3 (1 to 4) 0 (0 to 2)*** 1 (0 to 2)*** 4 (2 to 10)
AMS history N (%)
of those exposed
3 (25%) 2 (13%) 21 (34%) 4 (17%)* 6 (29%) 29 (38%)
Score values are expressed as mean ( – SD) or median (IQR). Differences among generations:*p < 0.05, ***p < 0.001 compared to adults
AMS, acute mountain sickness.
Table 2. AMS Scores [Median (IQR)] among Children (n= 87), Adolescents (n = 70), and Adults (n = 155)
LLS with sleep and clinical score LLS without sleep and clinical score
N HA1 HA2 HA1 HA2
Children 87 2.5 (2 to 4)* 2 (1 to 3)* 2 (1 to 3) 1 (1 to 2)
Adolescents 70 3 (2 to 5) 2 (1 to 4)*,{ 2 (1 to 3) 1 (0 to 2){
Adults 155 4 (3 to 5) 3 (2 to 4){ 2 (1 to 4) 1 (0 to 2){
Score values are expressed as median and interquartile range (IQR) of AMS scores (assessed by LLS).
*different from adults, {different from HA1.
HA1, day 1 at high altitude 8–10 hours after arrival; HA2, day 2 at high altitude 20–24 hours after arrival; LLS, Lake Louise Score.
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interactions between generation and gender were tested.
Mixed linear models were also used to assess differences in
scores across time or between instruments (LLS and CLLS),
with a special focus on potential heterogeneity across gen-
erations. To assess corresponding differences in binary out-
comes, we used linear regression with adjustment of standard
errors for clustering of data within families (PROC GEN-
MOD of SAS). In case of significant generation effects, an-
alyses were stratified between children, adolescents, and
adults. In addition, we tested agreement between a single
criterion question of the ESQ questionnaire (a value of equal
1 was given if there was at least a slight feeling of sickness)
and the LLS questionnaires by percentage of agreement (A)
and Cohen’s kappa (K) with 95% confidence intervals. At-
tractiveness of the different questionnaires was assessed by
asking the children which of the questionnaires they pre-
ferred. Statistical analyses were performed with the use of the
commercially available statistical package Stata 10. A p va-
lue of < 0.05 was considered significant.
Results
Baseline characteristics are shown in Table 1. As there
were no significant differences in AMS scores among the
three study periods or between genders (data not shown), data
were pooled. Significantly more adults documented having
had symptoms of AMS in the past, but data on children were
based on a limited past period. Thirty percent of all partici-
pants, irrespective of generation, had one or more AMS
symptoms at LA, mostly fatigue and/or headache. One adult
fulfilled the criteria for AMS at LA due to a migraine attack.
Scores and prevalence of AMS by age group are given in
Table 2 and 3, as well as in Figure 2. Two mothers, one with
an attack of severe migraine one h after arrival at HA, and the
other with severe dizziness and a panic-like feeling of being
sick, left soon after arrival. One prepubertal girl and one
adolescent boy had to be treated with dexamethasone 4 and
6 h after arrival due to severe AMS (both) and pulmonary
artery hypertension (girl) (Kriemler et al. 2006), respectively,
and had to be withdrawn from the study for day 2. Their data
were included for day 1, since the exams were taken prior to
treatment.
Cumulative prevalence of AMS assessed by the LLS
questionnaire was significantly lower in children (30%) as
compared to adolescents (37%) and adults (45%), respec-
tively ( p < 0.001). This was mainly due to lower AMS
scores and prevalence in children compared to adults at
HA1, but not HA2, while there was no difference between
adolescents and adults (Table 2). There was a significant
decrease in scores and prevalence over time in adolescents
and adults, whereas in children, they remained unchanged
between day 1 and 2. Seven (8%) children, nine (13%) ad-
olescents, and 19 (12%) adults had severe AMS with LLS
scores above 6 on HA1 or HA2 ( p = ns). Omiting the
symptom sleep from the LLS reduced prevalence signifi-
cantly in adolescents and adults but not in children. Pre-
valence of ‘‘being at least slightly sick’’ corresponded
reasonably well to a LLS-cutoff ‡ 5 (for children: A = 75%,
K = 0.5 [0.3–0.7]; for adolescents: A = 80%, K = 0.6 [0.4–
0.8]; for adults: A = 73%, K = 0.5 [0.4–0.6], respectively).
AMS scores, prevalence, and symptoms of the LLS and
CLLS in children were not different (see Appendix 1). The
inclusion of the intake of painkillers as covariate into the
model did not change results.
The prevalence of headache was lower in children com-
pared to the older groups on HA1, and lower in children and
adolescents compared to adults on HA2 (Table 4). Moreover,
sleep disturbances in children and adolescents were signifi-
cantly less prevalent than in adults. The other AMS symp-
Table 3. Prevalences of AMS [n (%)] at Day 1 (HA1), Day 2 (HA2), and Cumulative in Children, Adolescents,
and Adults upon Fast Exposure to High Altitude (3450 m) by the Use of the Lake Louise Questionnaire
( –Sleep/Clinical Score) and a General Question of Feeling at Least Slightly Sick
LLS ‡ 5
(with sleep/clinical score)
LLS ‡ 5 (without
sleep/clinical score)
feeling at least
slightly sick
n HA1 HA2 At any time HA1 HA2 At any time HA1 HA2 At any time
Children 87 18 (21)* 16 (18) 26 (30)* 14 (16) 9 (10){ 18 (21) 13 (15) 13 (15) 20 (23)
Adolescents 70 24 (34){ 13 (19) {,{ 26 (37){ 8 (11) 3 (4) 11 (16) 7 (10) 4 (6) 10 (14)
Adults 155 61 (39){ 38 (25) {,{ 69 (45){ 26 (17){ 16 (10) 39 (25){ 14 (9) 12 (8) 23 (14)
Values denote prevalences by numbers (percentage) of subjects with AMS or with the feeling of being sick.
*different from adults, {different from HA1 ( p < 0.05){ different between prevalence of being at least slightly sick and the LLS
questionnaire, p < 0.05.
HA1, day 1 at high altitude 8–10 hours after arrival; HA2, day 2 at high altitude 20–24 hours after arrival; LLS, Lake Louise Score;
feeling at least slightly sick = single question from the ESQ questionnaire asking: ‘‘Do you feel sick?’’ Positive answers given by a 6 point
Likert scale (from not at all= 0 to strongly= 6 with feeling at least slightly sick (Likert scale ‡ 2).
FIG. 2. Prevalence of AMS by Lake Louise score and day
1 (HA1) and day 2 (HA2) and cumulative of high altitude at
3500 m in children (n = 87), adolescents (n = 70), and adults
(n = 155).
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toms did not differ significantly between the groups. All
symptoms decreased over time; this was mostly significant
only for adolescents and adults. Ninety-five percent of chil-
dren liked the CLLS more than the LLS.
Figure 3 shows the concordance of AMS measured by the
cumulative LL-Score between youth and adults. OR were 5.1
(95% CI 1.1 to 23.2, p = 0.037) for children and adolescents to
have AMS with both parents compared to none of the parents
with AMS. If only one parent was affected, there was no
higher risk of AMS (OR 1.5 (0.5 to 5.1)). Overall, familial
clustering of AMS was consistent and accounted for 25%–
50% of total outcome variance, and was 27% for the cumu-
lated AMS prevalence by the LL-Score.
Results of the CPT are shown in Table 5. At LA, time in
cold water was significantly shorter in children and longer in
adolescents than in adults. At HA, it was shorter in children
than in adults. Time in cold water at LA was significantly
lower in those who developed AMS at HA than in the group
that did not develop AMS. This difference was larger and
statistically significant in children and adolescents. Time in
cold water at HA1 was significantly lower in adults with than
without AMS, while there was no difference for the younger
groups. SO2 differed neither among groups or days nor
among those with and without AMS.
Discussion
This is the first report of a study that prospectively inves-
tigated severity, pattern, and prevalence of AMS in families
comprising prepubertal children, adolescents, and adults
upon acute exposure to 3500 m. Children were less affected
by AMS on the first day of altitude exposure, whereas simi-
larly low scores were observed in all groups on the second
day of the altitude sojourn. The overall picture of the
symptom distribution was similar in all groups. Differences
in prevalence rates among generations were explained by less
sleep disturbances in children that might be explained by the
finding that children had less periodic breathing and therefore
less arousal during the night than adults (Kohler et al., 2008).
Children and adolescents from AMS affected parents showed
OR of 3.4 to 6.5 to be affected as well compared to those from
AMS-free parents. Overall, familial clustering explained
25%–50% of variability in AMS. Pain sensitivity increased at
HA, but interestingly, it was significantly higher in those
developing AMS compared to those that remained free of
AMS. Differences in SO2 between those with and without
AMS did not exist.
Strengths and limitations of study
We investigated AMS prevalence in prepubertal children,
adolescents, and adults under standardized conditions at an
altitude that is often reached in professional and recreational
life. The results reassure that children tolerate high altitude at
least as well as adults. Even prepubertal children from an age
of 9 years on could easily report symptoms of AMS by a
Table 4. Prevalence of AMS Symptoms [n (%)] by the
Lake Louise Questionnaire among Children (n = 87),
Adolescents (n = 70) and Adults (n = 155)
HA1 HA2
Headache
Children 41 (47)* 34 (39)*
Adolescents 45 (64) 23 (33)*,{
Adults 111 (72) 79 (51){
Gastrointestinal symptoms
Children 20 (23) 19 (22)
Adolescents 10 (14) 8 (11)
Adults 33 (21) 32 (21)
Fatigue
Children 67 (77) 54 (62){
Adolescents 61 (87) 43 (61){
Adults 120 (77) 95 (61){
Dizziness
Children 22 (25) 14 (16)
Adolescents 21 (30) 11 (16){
Adults 60 (39) 20 (13){
Sleep disturbance
Children 54 (62)*
Adolescents 50 (71)*
Adults 134 (86)
Values are expressed as numbers (percentage) of subjects with a
specific symptom by the LLS questionnaire.
*different from adults, {different from HA1, significance level
p < 0.05.
HA1, 8–10 hours after arrival; HA2, 20–24 hours after arrival,
sleep disturbance refers to the night between HA1 and HA2; LLS,
Lake Louise Score.
FIG. 3. Significant concordance of AMS within 123
families. Bars denote the population of youth (58 children
and 65 adolescents) and the correspondeing parents-pairs
(34 single parent families excluded) categorized into AMS
+ /+ (both parents affected), AMS + / - (one parent af-
fected), and AMS - / - (both parents healthy). Odds Ratio
(OR) was calculated taking family clustering into account.
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simple questionnaire, such as the LLS score. Moreover, the
layout of the study enabled us to look at familial clustering of
AMS which indeed occurred. Limitations of the study in-
clude the three different time periods used to run the study
including a slightly different altitude ( + 200 m) and a dif-
ferent place of overnight stay. Yet, this is real life and none of
the outcomes differed. Moreover, an altitude difference of
200 m is related to an ambient pressure difference compara-
ble to the variability by weather conditions. It needs to be
noted that we did not investigate younger children (< 9
years). The history of AMS among generations cannot be
taken as reliable source of information as children have a very
limited past compared to adults. Due to parallel measure-
ments of ventilatory parameters in some of the participants
(not reported here), we asked all subjects to abstain from
caffeine intake that may have biased the study results due to
the potential occurrence of withdrawal headaches( Juliano
and Griffiths, 2004). And finally, analyses of familial clus-
tering of AMS were only done in families in which both
parents took part, potentially limiting generalizability of
findings.
Comparison with other studies
Although similar prevalence and severity of AMS in
children of different age in comparison to adults has been
suggested (Pollard et al., 2001; Kohler et al., 2008; Bloch
et al., 2009), it has never been proven in sufficiently large,
standardized trials. The prevalence of AMS in our study was
comparable to other studies in adults (Maggiorini et al.,
1990; Hackett and Roach, 2001) and adolescents (Bloch
et al., 2009), although some higher or lower rates have also
been reported (Hackett and Roach, 2001). Since different
ascent speed, latitudes, and different diagnostic criteria
were used, this is neither surprising nor contradictory
(Schneider et al., 2002), but still might represent differences
in individual susceptibility in different populations. Pre-
vious studies included much smaller numbers of children
(Moraga et al., 2002; Moraga et al., 2008; Bloch et al., 2009;
Pradhan et al., 2009) compromising generalizability. As
previously shown, there was no significant difference in
AMS prevalence between females and males (Hackett et al.,
1976; Maggiorini et al., 1990). Only a tenth of the popula-
tion had severe AMS with LLS scores above 6 at HA1 or
HA2, and nobody developed high altitude pulmonary or
cerebral edema.
There is no best way to document AMS as it is a subjec-
tively assessed symptom complex combined with some
clinical signs. Most scientists nowadays use the LLS, which
is simple to use and translated into many languages. As
shown in this study, the questionnaire can also be used for
children from school age on. The value of including sleep
disturbances is open for debate as assessment of sleep dis-
turbances to determine AMS the first day of altitude exposure
cannot be done, and there may not be an ‘‘ill-value’’ in an
environment of reduced sleep comfort in huts and dormito-
ries. This may be the reason why concordance of ‘‘being at
least slightly sick’’ was higher when the symptom sleep was
omitted from AMS scores (see Table 3). Yet, there was still a
significant difference in adults (not in children and adoles-
cents) between AMS prevalence and the ‘‘ill-feeling ques-
tion’’ which is not easily explained. A possible explanation
may be that many altitude-experienced adults don’t perceive
T
a
b
l
e
5
.
M
e
d
ia
n
s
o
f
C
o
l
d
P
r
e
ss
u
r
e
T
a
sk
(C
P
T
)
a
n
d
o
f
O
x
y
g
e
n
S
a
t
u
r
a
t
io
n
(S
O
2
)
in
S
u
b
je
c
t
s
W
it
h
a
n
d
W
it
h
o
u
t
A
M
S
A
c
c
o
r
d
in
g
t
o
G
r
o
u
p
L
o
w
a
lt
it
u
d
e
(L
A
)
H
ig
h
a
lt
it
u
d
e
(H
A
)
C
o
ld
P
re
ss
u
re
T
a
sk
(C
P
T
,
s)
n
a
ll
A
M
S
N
o
A
M
S
n
a
ll
A
M
S
N
o
A
M
S
C
h
il
d
re
n
5
2
7
3
(2
9
to
2
4
0
)*
3
0
(1
8
to
9
0
){
2
4
0
(4
5
to
2
4
0
)
6
5
4
3
(3
0
to
2
4
0
)*
3
8
.5
(2
5
to
7
3
)
4
7
(3
0
to
2
4
0
)
A
d
o
le
sc
en
ts
4
7
2
4
0
(2
4
0
to
2
4
0
)*
2
4
0
(5
5
to
2
4
0
){
2
4
0
(2
4
0
to
2
4
0
)
7
0
2
4
0
(5
7
to
2
4
0
)
2
4
0
(4
3
to
2
4
0
)
1
8
0
(5
9
.5
to
2
4
0
)
A
d
u
lt
s
1
0
0
2
4
0
(6
0
to
2
4
0
)
2
4
0
(5
8
to
2
4
0
)
2
4
0
(6
4
to
2
4
0
)
1
3
5
9
8
(4
0
to
2
4
0
)
7
2
(3
4
to
2
4
0
)
2
4
0
(4
6
.5
to
2
4
0
)
A
ll
1
9
9
2
4
0
(5
5
to
2
4
0
)
2
4
0
(3
5
to
2
4
0
){
2
4
0
(6
3
.5
to
2
4
0
)
2
7
0
8
1
(3
8
to
2
4
0
),
{
7
2
(3
3
to
2
4
0
){
9
8
(3
9
to
2
4
0
){
D
a
y
1
o
f
H
ig
h
a
lt
it
u
d
e
(H
A
1
)
D
a
y
2
o
f
H
ig
h
a
lt
it
u
d
e
(H
A
2
)
O
xy
g
en
sa
tu
ra
ti
o
n
(S
O
2
,
%
)
n
a
ll
A
M
S
N
o
A
M
S
n
a
ll
A
M
S
N
o
A
M
S
C
h
il
d
re
n
8
6
8
5
(8
3
to
8
8
)
8
3
(8
0
to
8
7
)
8
6
(8
4
to
8
9
)
8
6
8
6
(8
2
to
8
9
)
8
5
(8
0
to
8
7
)
8
6
(8
3
to
9
0
)
A
d
o
le
sc
en
ts
6
7
8
6
(8
4
to
8
9
)
8
6
(8
3
to
8
8
)
8
7
(8
4
to
8
9
)
6
8
8
6
(8
2
to
9
0
)
8
6
(8
2
to
8
9
)
8
6
(8
3
to
9
0
)
A
d
u
lt
s
1
5
1
8
5
(8
2
to
8
8
)
8
4
(8
1
to
8
7
$5
)
8
6
(8
3
to
8
9
)
1
5
0
8
6
.5
(8
3
to
8
9
)
8
6
(8
3
to
8
9
)
8
7
(8
3
to
8
9
)
A
ll
3
0
4
8
6
(8
2
$7
5
to
8
8
)
8
4
(8
1
to
8
8
)
8
6
(8
3
.5
to
8
9
)
3
0
4
8
6
(8
3
to
8
9
)
8
6
(8
2
to
8
9
)
8
7
(8
3
to
8
9
)
S
co
re
v
al
u
es
ar
e
ex
p
re
ss
ed
as
m
ed
ia
n
an
d
in
te
rq
u
ar
ti
le
ra
n
g
e
(I
Q
R
);
O
f
n
o
te
:
C
P
T
w
as
n
o
t
p
er
fo
rm
ed
in
th
e
fi
rs
t,
b
u
t
o
n
ly
in
th
e
se
co
n
d
an
d
th
ir
d
st
u
d
y
p
er
io
d
.
*
d
if
fe
re
n
t
fr
o
m
ad
u
lt
s,
{d
if
fe
re
n
t
fr
o
m
n
o
A
M
S
,
{ d
if
fe
re
n
t
fr
o
m
lo
w
al
ti
tu
d
e,
si
g
n
ifi
ca
n
ce
le
v
el
p
<
0
.0
5
.
6 KRIEMLER ET AL.
symptoms of AMS as a state of sickness, but rather take it as
normal adaptation to high altitude and know that symptoms
usually cease within little time.
Several studies have found specific genes that may, beside
an environmental component, help to explain high altitude
disease (MacInnis et al., 2010), but few have looked at epi-
demiological patterns or familial clustering that would be
consistent with genetically influenced conditions (Yaron,
2001). This is the first study clearly documenting clustering
of AMS within families with a high concordance between
children and parents in AMS prevalence as classical marker
of a genetically influenced trait. OR were 5-fold in children
and adolescents to get AMS with both parents compared to no
parents affected. Further studies with more participants may
reveal whether there exist genes associated with biological
pathways of AMS, or whether these findings are rather or also
explained by intra-familial behavioral patterns, as shown in
other domains (Christakis and Fowler, 2007).
Pain sensitivity to cold increased from normoxia to
hypoxia and was higher in those with AMS. There is one
study that tested pain thresholds and discrimination per-
formances of electrical stimuli to the skin at low altitude and
6 days later at 3500m in adult lowlanders (Noel-Jorand
et al., 1996). They found increased sensory discrimination
and reduced thresholds to detect pain at comparable alti-
tudes in a subacute hypoxic setting. They also measured
psychological attitude towards imagined painful situations
which did not change at high altitude, suggesting that in-
creased sensory discrimination of pain is an adaption to
hypoxia. These findings are in accordance to our findings of
lower pain tolerances upon acute exposure to HA which
hypothetically may facilitate ventilatory acclimatization
due to an earlier onset of respiratory and other sensory
perceptions (Noel-Jorand, 1996). Although pain sensitivity
was higher in those with AMS at LA, it did not discriminate
sufficiently to be used as screening test. Yet, it may partly
explain the occurrence and severity of pain related symp-
toms such as headache.
Despite the fact that oxygen saturation is an easy mea-
surable, noninvasive test often being recommended for di-
agnostic reasons, as it correlated with AMS (Roach et al.,
1998; Burtscher et al., 2004), it was not a predictor of AMS in
our study. Overall, SO2 values did not differ between groups
with or without AMS. This is in agreement with some (Chen
et al., 2012; Wagner et al., 2012), but not all studies (Karinen
et al., 2010, 2012). Moreover, oxygen saturation may be
difficult to measure in a standardized way depending on the
conditions in the field. Also, multiple other factors affect the
oxygen-dissociation curve such as age, hemoglobin concen-
tration, plasma volume shifts, or cold in mountaineers ex-
posed to HA. Therefore, measures of SO2 at HA have to be
interpreted with sufficient caution.
Implications of study
AMS affected about one in five children during the first 2
days of altitude exposure to 3500 m that can easily be mea-
sured by the adults’ or children’s version of the LLS. AMS
scores were in all generations mild to at most moderate and
no serious problems were seen. Only on rare occasions (1%–
2% in our sample), more severe AMS in children and ado-
lescents may occur (Pollard et al., 2001; Kriemler et al.,
2006), requesting medical treatment and/or immediate de-
scent. These events were not life-threatening and disappeared
quickly after treatment or descent. Thus, there are no reasons
to discourage families with children aged 9 years or older to
travel to high altitude. There are no studies about effects of
treatment modalities in children with AMS, but body mass
adapted evidence-based medications for adults seem to work
similarly for all generations (Pollard et al., 2001).
Unanswered questions and future research
AMS prevalence and severity in children below the age of
9 years has not yet been sufficiently studied. We did not find
any evidence that AMS prevalence and severity may increase
with lower age, but appropriate family-based studies in-
cluding measures focusing on heritability of high altitude
illness are required to address this question. Even in adults,
mechanisms of AMS secondary to (hypobaric) hypoxia are
not well understood and should be studied in more detail.
Postulated physiological responses potentially involved in
AMS such as hypoventilation, impaired gas exchange, in-
creased sympathetic drive, or alterations in fluid homeostasis
should be specifically addressed in future research, including
both adults and children. Likewise, emergency medications
that may be applied in case of severe AMS including po-
tentially harmful steroids should be tested in clinical trials,
but due to increasingly precautious ethical committees, par-
ticularly in children, this might never happen.
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Appendix 1
A. AMS Scores and Prevalence of the LLS Compared to CLLS Questionnaire
in Children upon Fast Exposure to High Altitude (3450 m)
LLS ‡ 5 (with sleep/clinical score) CLLS ‡ 5 (with sleep/clinical score)
n HA1 HA2 At any time HA1 HA2 At any time
Score 67 3 (2 to 4)* 2 (1 to 3) – 2 (1 to 4) 2 (1 to 4) –
Prevalence 67 13 (20) 12 (18) 18 (28) 12 (18) 13 (20) 20 (31)
Values denote AMS scores by median (interquartile range) and prevalence by n (%) based on the adult version (LLS) and an adapted
child version (CLLS) of the Lake Louise Score. Prevalence is based on a cutoff of ‡ 5 including the symptom sleep and the clinical score.
AMS= acute mountain sickness; HA1= day 1 of high altitude; HA2 = day 2 of high altitude.
B. Distribution [n (%)] of AMS Symptoms of the LLS and CLLS Questionnaires
in Children (n = 67) at High Altitude
Score 0 Score 1 Score 2 Score 3
LLS CLLS LLS CLLS LLS CLLS LLS CLLS
Headache
HA1 33 (49) 33 (49) 23 (34) 24 (36) 9 (13) 8 (12) 2 (3) 2 (3)
HA2 42 (63) 39 (58) 21 (31) 25 (37) 3 (4) 2 (3) 1 (2) 1 (2)
GI
HA1 52 (78) 51 (76) 12 (18) 12 (18) 2 (3) 4 (6) 1 (2) 0
HA2 54 (80) 45 (67) 8 (12) 16 (24) 5 (5) 6 (9) 0 0
Fatigue
HA1 15 (22) 13 (19) 42 (63) 43 (64) 10 (15) 9 (13) 0 2 (3)
HA2 27 (40) 24 (36) 34 (51) 34 (51) 3 (4) 5 (7) 3 (4) 4 (6)
Dizziness
HA1 49 (73) 53 (79) 17 (25) 13 (19) 1 (2) 1 (2) 0 0
HA2 56 (84) 57 (85) 9 (13) 9 (13) 2 (3) 1 (2) 0 0
Sleep
HA1 51 (76) 49 (73) 12 (18) 13 (19) 4 (6) 5 (7) 0 0
HA2 26 (39) 28 (42) 25 (37) 24 (36) 15 (22) 14 (21) 1 (2) 1 (2)
Values denote numbers and percentage of children with the respective symptom.
LLS=Lake Louise Score; CLLS=Children Lake Louise Score; HA1= day 1 of high altitude; HA2 = day 2 of high altitude.
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C. Example of the Adapted Version of the Children Lake Louise Questionnaire (CLLS)
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